DNA Test for Heart Disease Risk in India: What Your Genes Actually Reveal

South Asians have a 3 to 4 times higher risk of coronary artery disease (CAD) than Europeans — and it strikes earlier. The average age of a first heart attack in Indian men is 53. In Western men, it is 65. That is a twelve-year gap that cannot be explained by diet or lifestyle alone. Genetics is a significant and underappreciated part of the picture.

This is not simply about high cholesterol. Many Indians who suffer cardiac events have cholesterol levels that look entirely normal on a standard blood test. There are specific genetic variants — some of them almost exclusive to South Asians — that drive risk through entirely different mechanisms. Understanding which ones you carry is the starting point for a more precise conversation with your cardiologist.

Why Indians Are at Higher Cardiac Risk: The Genetic Dimension

Population-level cardiac risk in South Asians involves a cluster of factors: smaller vessel diameter, higher rates of abdominal obesity at lower BMIs, different lipid metabolism profiles, and a higher prevalence of certain genetic variants compared to European populations. Some of these differences are well understood. Others are still being mapped.

What is increasingly clear from large-scale genomic studies is that several specific loci in the human genome contribute to Indian cardiac risk in ways that standard clinical risk assessment — cholesterol panels, blood pressure readings, BMI — does not capture. Knowing your genetic profile at these loci does not replace clinical assessment, but it adds a layer of information that changes the conversation.

Key Cardiac Risk Genes: What the Evidence Shows

MYBPC3 — The South Asian Cardiac Gene

This is the most significant South Asia–specific cardiac genetic variant identified to date. A 25 base pair deletion in the MYBPC3 gene — which encodes cardiac myosin binding protein C, a structural protein in heart muscle — is present in approximately 4% of South Asians. That translates to roughly 50 to 60 million carriers across the Indian subcontinent. The same variant is almost completely absent in European, East Asian, and African populations.

Carriers of this deletion have a substantially elevated risk for hypertrophic cardiomyopathy (HCM) — a condition where the heart muscle thickens abnormally. HCM is the leading cause of sudden cardiac death in young people, including young athletes. Crucially, many HCM carriers have no symptoms until a sudden event. An echocardiogram can detect the structural changes long before symptoms appear, which is exactly why knowing your MYBPC3 status matters.

APOE — Cholesterol, Cardiovascular Risk, and More

The APOE gene encodes apolipoprotein E, a protein involved in lipid metabolism. There are three main variants — APOE2, APOE3, and APOE4. APOE4 is associated with elevated LDL cholesterol and increased cardiovascular risk. It is also the single strongest known genetic risk factor for late-onset Alzheimer's disease. One in four people globally carries at least one copy of APOE4.

For cardiac purposes, APOE4 carriers tend to have higher circulating LDL and may respond differently to dietary interventions. APOE2, conversely, is associated with lower LDL but can in rare cases cause type III hyperlipidaemia, a condition that markedly increases cardiovascular risk through a different mechanism. Origins+ covers APOE variants, giving you information relevant to both cardiac and cognitive risk in a single report.

LDLR — Familial Hypercholesterolaemia

Variants in the LDLR gene (low-density lipoprotein receptor) are the most common cause of familial hypercholesterolaemia (FH) — a genetic condition that causes severely elevated LDL from birth regardless of diet. FH affects approximately 1 in 300 people globally, making it one of the most common inherited cardiac conditions. In India, it is vastly underdiagnosed.

Untreated FH dramatically accelerates atherosclerosis. Men with untreated FH have a 50% risk of a significant cardiac event by age 50. Women face a 30% risk by age 60. Yet because it is underdiagnosed, many carriers discover their risk only after a first event. Genotyping key LDLR variants is a first-line screen — though a comprehensive clinical FH panel may be needed if suspicion is high and your SNP result is negative.

PCSK9 — The LDL Regulator

PCSK9 regulates how many LDL receptors your liver makes. Gain-of-function variants cause the liver to clear fewer LDL particles, driving higher circulating LDL and increasing cardiovascular risk. Loss-of-function variants do the opposite — carriers have naturally lower LDL and are substantially protected against CAD. This is the genetic insight that led to the development of the PCSK9 inhibitor drug class, now among the most powerful lipid-lowering treatments available.

Knowing your PCSK9 status is clinically relevant: gain-of-function carriers may need earlier or more aggressive statin therapy; loss-of-function carriers have a naturally protective variant worth understanding in the context of their overall risk profile.

The 9p21 Locus — The Most Replicated CAD Risk Factor

A region on chromosome 9 — designated 9p21 — contains the most consistently replicated genetic risk factor for coronary artery disease across multiple large genome-wide association studies. The exact mechanism is still being studied (the region contains no protein-coding genes, only regulatory elements), but its effect is clear: certain common SNPs in this region independently raise CAD risk by approximately 25 to 35%, regardless of cholesterol levels, blood pressure, or other risk factors.

The 9p21 risk variant is surprisingly common — present in approximately 25% of Europeans — and acts through mechanisms that are entirely separate from the lipid pathway. A person with normal cholesterol, healthy blood pressure, and no family history can still carry 9p21 risk variants. This is one reason why genetic cardiac screening can add information that purely clinical risk tools miss.

What Consumer DNA Testing Can and Cannot Tell You

Helixline's Origins+ uses SNP microarray genotyping. The test reads approximately 700,000 to 900,000 specific positions across your genome that have been established as clinically or scientifically meaningful. For cardiac genetics, this covers:

• The MYBPC3 25bp deletion (the key South Asian cardiomyopathy variant)
• APOE variants (E2/E3/E4 status)
• Key PCSK9 variants (gain-of-function and loss-of-function)
• LDLR variants associated with familial hypercholesterolaemia
• 9p21 locus SNPs
• Statin pharmacogenomics (CYP3A4, CYP3A5)

What a consumer SNP test cannot do: detect rare or novel mutations that are not on the genotyping array; sequence the full coding regions of cardiac genes (that requires whole-exome or targeted panel sequencing); identify all possible FH-causing mutations (hundreds exist, most rare); or detect structural variants and copy number variations beyond those specifically included on the array.

The honest summary: an Origins+ result is highly informative for the most common, most well-established cardiac risk variants in the South Asian population. It is not equivalent to a clinical cardiac genetic panel ordered by a cardiologist after a high-risk diagnosis. These are complementary tools, not competing ones.

Who Should Prioritise Cardiac Genetic Testing

Certain profiles make cardiac genetic testing particularly worthwhile:

• Family history of early heart attack: A father or brother who had a heart attack before 55, or a mother or sister before 65, is a strong indication that genetic factors are at play.
• Unexplained high LDL despite healthy diet: If your LDL remains elevated at 200+ mg/dL despite dietary changes, LDLR or PCSK9 gain-of-function variants are a plausible cause worth investigating.
• Young athlete with palpitations: Unexplained palpitations, shortness of breath on exertion, or a family member who died suddenly during exercise — MYBPC3 testing is directly relevant.
• Before starting statins: Pharmacogenomics for CYP3A4/5 before statin initiation helps your cardiologist choose the right drug and starting dose — reducing both under-treatment and side effect risk.
• Proactive baseline for a family planning to monitor health over decades: If cardiac disease runs in your family and you want a genetic baseline before symptoms ever appear, a 30s or 40s test gives you the most useful lead time.

Origins+ Cardiac Coverage: What You Get

Origins+ (₹12,999) is Helixline's comprehensive health and ancestry kit. On the cardiac side, the report covers:

• MYBPC3 deletion status with population context (you will see your carrier status relative to the broader South Asian population)
• APOE genotype with both cardiovascular and cognitive risk context
• 9p21 locus risk variants with absolute and relative risk estimates
• PCSK9 variant status (gain-of-function and protective loss-of-function variants)
• LDLR variants for familial hypercholesterolaemia risk
• Statin pharmacogenomics: CYP3A4 and CYP3A5 status affects how your body processes atorvastatin, simvastatin, lovastatin, and rosuvastatin. The report identifies whether you are a normal, intermediate, poor, or rapid metaboliser — information a cardiologist can use directly when discussing drug selection

How to Act on Your Results

A positive result — meaning you carry a risk variant — is a signal, not a sentence. Here is how to approach each scenario:

If you test positive for MYBPC3

Schedule an appointment with a cardiologist and ask for an echocardiogram. An echo can directly visualise whether hypertrophic changes have begun in the heart muscle. If the echo is normal, regular monitoring every few years is appropriate. Your first-degree relatives (parents, siblings, children) should also be offered testing — cascade testing in families is the standard approach for HCM.

If you carry APOE4

Be more vigilant about cardiovascular risk factors — blood pressure, LDL, blood sugar — because APOE4 compounds their effect. Discuss the Alzheimer's risk implications with your doctor separately; many people choose to know this information to shape lifestyle decisions, while others prefer not to. The choice is yours.

If you carry 9p21 risk variants

This is a risk modifier, not a standalone determinant. Combined with standard clinical risk factors (lipids, blood pressure, smoking, diabetes), 9p21 status gives your cardiologist a more complete picture. It typically argues for more aggressive management of modifiable risk factors — particularly if the overall clinical risk score is already borderline.

If pharmacogenomics flags statin metabolism concerns

Share the pharmacogenomics report with your prescribing doctor before starting or adjusting statin therapy. A poor metaboliser may need a lower dose or a different statin. A rapid metaboliser may need a higher dose to achieve the same LDL reduction. This is exactly the information that makes pharmacogenomics useful in practice — it is not theoretical, it directly informs prescribing decisions.

Prevention Is the Point

The 12-year gap between the average age of first heart attack in Indian men versus Western men is not inevitable. It reflects a combination of genetic susceptibility, earlier exposure to risk factors, and — critically — underdiagnosis and undertreatment. Indian cardiac risk is systematically underestimated by clinical tools designed for European populations.

Knowing your cardiac genetic profile is not about triggering anxiety. It is about replacing uncertainty with information. A person who knows they carry the MYBPC3 deletion can get an echocardiogram at 35 and be reassured, or catch structural changes early and manage them before a crisis. A person who discovers an elevated 9p21 risk profile can start a statin discussion with their cardiologist a decade earlier than they might have otherwise. The first event is the worst time to discover a genetic risk you could have known about years before.

DNA testing does not prevent heart attacks by itself. But it starts the right conversations — and sometimes the right conversation, started early enough, makes all the difference.

Frequently Asked Questions

If I test positive for the MYBPC3 variant, does that mean I'll have a heart attack?

No. Carrying the MYBPC3 25bp deletion variant means you have a significantly elevated risk for hypertrophic cardiomyopathy — not a certainty of heart disease. Many carriers live without symptoms. What it means practically: your cardiologist should know, you should likely have an echocardiogram, and close relatives should be offered cascade testing. It is a risk signal, not a diagnosis.

What's the difference between a consumer DNA cardiac test and a clinical cardiac genetic panel?

A consumer SNP test like Origins+ genotypes hundreds of thousands of known positions in your DNA against a fixed array, covering common variants at established cardiac risk loci including MYBPC3, APOE, PCSK9, and 9p21. A clinical cardiac genetic panel sequences the full coding regions of 30 to 100+ cardiac genes and can detect rare or novel mutations that do not appear on a standard array. For most people with no strong family history, a consumer test is informative. For those with a family history of sudden cardiac death or confirmed cardiomyopathy, a clinical panel is appropriate.

Can Origins+ detect familial hypercholesterolaemia (FH)?

Partially. Origins+ genotypes key common variants in LDLR and PCSK9 associated with familial hypercholesterolaemia. However, FH is caused by hundreds of different mutations across LDLR, APOB, and PCSK9 — many of which are rare and not on any standard SNP array. A negative result on Origins+ does not rule out FH. If your LDL remains very high despite lifestyle changes, or you have a first-degree relative diagnosed with FH, request a dedicated clinical FH genetic panel from your doctor.

How does pharmacogenomics help with heart disease management?

Pharmacogenomics looks at how your genetics affect how your body metabolises drugs. For cardiac patients, the most relevant example is statins. CYP3A4 and CYP3A5 variants affect how quickly your liver breaks down statins like atorvastatin and simvastatin. Slow metabolisers accumulate higher drug levels, increasing the risk of myopathy (muscle damage). Rapid metabolisers clear the drug too quickly and may not reach therapeutic levels at standard doses. Origins+ covers statin pharmacogenomics, giving you and your cardiologist data to optimise drug choice and dose rather than relying purely on trial and error.

My cholesterol is normal but my father had a heart attack at 48 — should I get genetic testing?

Yes, this is exactly the scenario where genetic testing adds real value. A paternal heart attack before 55 is a major family history risk factor. Normal cholesterol does not rule out genetic cardiac risk — the 9p21 locus independently raises CAD risk regardless of LDL levels. The MYBPC3 deletion also does not affect cholesterol at all but still causes structural heart changes. Starting with Origins+ gives you a broad sweep of established risk variants. If results are positive, or if your clinical risk score remains high, a cardiologist can order a comprehensive cardiac panel.